Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing of a $53 million financing from its existing syndicate of top-tier investors.
The financing will support Ensoma’s recently initiated Phase 1/2 clinical trial for EN-374 in X-linked chronic granulomatous disease (X-CGD) and support key clinical readouts, while continuing to expand and refine the potential global impact of the company’s in vivo engineered cell therapy platform in immuno-oncology and sickle cell disease.
Read More – Phia Raises $8M in Seed Funding
Investors include Gilead (Nasdaq: GILD), which has also appointed an executive to the Ensoma board of directors as part of its investment, as well as 5AM Ventures, Catalio Capital Management, Cormorant Asset Management, Delos Capital, F-Prime, the Gates Foundation, Hanwha Impact Partners, Mirae Asset Financial Group, Qatar Investment Authority (QIA), RTW, Solasta Ventures, SymBiosis and Viking Global Investors.
“The $53 million financing reflects growing interest in our platform’s potential to address serious diseases through one-time, outpatient treatments,” said Jim Burns, CEO of Ensoma. ”This is a defining moment for Ensoma as we are now a clinical-stage company and recruiting participants for our Phase 1/2 trial for EN-374 to treat X-linked CGD. With a strong manufacturing foundation in place, as well, we are in a strong position to begin generating meaningful human data for our first-in-class in vivo HSC-directed therapy.”
Read More – Earthmover Raises $7.2M in Seed Funding
